Texas Permanent School Fund lowered its stake in Pfizer Inc. (NYSE:PFE) by 7.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,427,434 shares of the biopharmaceutical company’s stock after selling 110,658 shares during the quarter. Pfizer makes up approximately 0.7% of Texas Permanent School Fund’s investment portfolio, making the stock its 19th largest position. Texas Permanent School Fund’s holdings in Pfizer were worth $51,787,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of PFE. HC Financial Advisors Inc. purchased a new stake in Pfizer during the 4th quarter valued at about $2,685,000. Investors Research Corp purchased a new stake in Pfizer during the 4th quarter valued at about $833,000. Yorktown Management & Research Co Inc grew its stake in Pfizer by 53.6% during the 4th quarter. Yorktown Management & Research Co Inc now owns 55,900 shares of the biopharmaceutical company’s stock valued at $2,025,000 after purchasing an additional 19,500 shares during the last quarter. Northstar Wealth Partners LLC grew its stake in Pfizer by 5.1% during the 4th quarter. Northstar Wealth Partners LLC now owns 54,586 shares of the biopharmaceutical company’s stock valued at $1,990,000 after purchasing an additional 2,626 shares during the last quarter. Finally, Bell & Brown Wealth Advisors LLC purchased a new stake in Pfizer during the 4th quarter valued at about $1,421,000. 68.95% of the stock is owned by hedge funds and other institutional investors.

In other Pfizer news, VP Loretta V. Cangialosi sold 26,814 shares of the stock in a transaction that occurred on Wednesday, August 1st. The stock was sold at an average price of $40.16, for a total transaction of $1,076,850.24. Following the completion of the transaction, the vice president now owns 102,360 shares of the company’s stock, valued at $4,110,777.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Laurie J. Olson sold 10,214 shares of the stock in a transaction that occurred on Monday, August 13th. The shares were sold at an average price of $41.00, for a total value of $418,774.00. Following the transaction, the insider now directly owns 72,672 shares of the company’s stock, valued at approximately $2,979,552. The disclosure for this sale can be found here. Insiders sold a total of 761,230 shares of company stock valued at $29,054,690 in the last ninety days. 0.06% of the stock is currently owned by insiders.

A number of analysts have recently commented on the company. Cantor Fitzgerald set a $45.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Thursday, October 4th. Morgan Stanley set a $45.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, August 29th. Credit Suisse Group upped their target price on Pfizer from $39.00 to $40.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 1st. Bank of America upped their target price on Pfizer from $42.00 to $43.00 and gave the stock a “buy” rating in a research note on Wednesday, August 1st. Finally, JPMorgan Chase & Co. restated a “$37.66” rating on shares of Pfizer in a research note on Wednesday, July 18th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating and nine have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $42.40.

NYSE PFE traded up $0.97 during trading hours on Friday, reaching $43.78. The company’s stock had a trading volume of 28,490,527 shares, compared to its average volume of 21,858,029. The stock has a market capitalization of $262.34 billion, a price-to-earnings ratio of 16.52, a PEG ratio of 2.23 and a beta of 0.96. Pfizer Inc. has a 1-year low of $33.20 and a 1-year high of $45.81. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.41.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.07. The company had revenue of $13.47 billion during the quarter, compared to analysts’ expectations of $13.30 billion. Pfizer had a return on equity of 25.35% and a net margin of 42.35%. Pfizer’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.67 EPS. Equities analysts predict that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Friday, November 9th will be issued a $0.34 dividend. The ex-dividend date is Thursday, November 8th. This represents a $1.36 dividend on an annualized basis and a yield of 3.11%. Pfizer’s payout ratio is 51.32%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Featured Article: What Does Beta Mean In Stock Selection

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.